Drugmaker Merck has officially asked the FDA to authorize its pill for COVID-19, saying it can reduce the risk of hospitalization. But, just how much of a gamechanger could it really be? READ MORE: ...

WASHINGTON - Pfizer said Tuesday that its experimental COVID-19 pill appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill's ...

The findings may increase scrutiny about the usefulness of the treatment, molnupiravir, which was one of the first Covid drugs available to doctors worldwide during the pandemic. Molnupiravir works by ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.

Pfizer announced Tuesday that it is seeking emergency use authorization from the US Food and Drug Administration for its experimental antiviral Covid-19 pill, known as PF-07321332 or Paxlovid. Pfizer ...

Add Yahoo as a preferred source to see more of our stories on Google. One study estimated that in their first year of use, Covid-19 vaccinations averted almost 20 million deaths around the world. - ...

Stream Connecticut News for free, 24/7, wherever you are. The findings may increase scrutiny about the usefulness of the treatment, molnupiravir, which was one of the first Covid drugs available to ...